Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.
作者信息
Duseja Ajay, Dhiman Radha K, Premkumar Madhumita
机构信息
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
出版信息
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):159-162. doi: 10.1016/j.jceh.2020.07.008. Epub 2020 Jul 24.
Abstract
摘要
相似文献
1
Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.非酒精性脂肪性肝病：过去五年的经验教训
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):159-162. doi: 10.1016/j.jceh.2020.07.008. Epub 2020 Jul 24.
2
Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.虾青素和安卡黄素作为天然 AMPK 激活剂，具有 PPARα 激动剂活性，可下调高脂饮食喂养的 C57BL/6 小鼠的非酒精性脂肪性肝炎。
Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22.
3
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).印度国家肝脏研究协会（INASL）关于非酒精性脂肪性肝病（NAFLD）命名、诊断和治疗的指导文件。
J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7.
4
Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.非酒精性脂肪性肝病的自然史：一项配对肝活检研究
J Clin Exp Hepatol. 2020 May-Jun;10(3):245-254. doi: 10.1016/j.jceh.2019.07.002. Epub 2019 Jul 15.
5
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.生物信息学分析揭示了与非酒精性脂肪性肝病和非酒精性脂肪性肝炎相关的新核心基因。
Gene. 2020 Jun 5;742:144549. doi: 10.1016/j.gene.2020.144549. Epub 2020 Mar 14.
6
[The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].[过氧化物酶体增殖物激活受体双重/泛激动剂作为抗非酒精性脂肪性肝病治疗药物的前景]
Yakugaku Zasshi. 2022;142(12):1335-1343. doi: 10.1248/yakushi.22-00159-1.
7
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.非酒精性脂肪性肝病之谜：从非酒精性脂肪肝到非酒精性脂肪性肝炎的进展
J Clin Exp Hepatol. 2015 Jun;5(2):147-58. doi: 10.1016/j.jceh.2015.02.002. Epub 2015 Feb 16.
8
Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.过氧化物酶体增殖物激活受体α和γ2 多态性与非酒精性脂肪性肝病：巴西患者的研究。
Gene. 2013 Oct 25;529(2):326-31. doi: 10.1016/j.gene.2013.06.091. Epub 2013 Jul 24.
9
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.与健康正常体重个体相比，不同程度非酒精性脂肪性肝病患者的肝转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
10
Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.非酒精性脂肪性肝病与非酒精性脂肪性肝炎：病理与临床意义。
Curr Vasc Pharmacol. 2018;16(3):214-218. doi: 10.2174/1570161115666170621075157.
引用本文的文献
1
Association of Subclinical Hypothyroidism with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.2型糖尿病患者亚临床甲状腺功能减退与非酒精性脂肪性肝病的关联：一项横断面研究
Adv Biomed Res. 2022 Dec 26;11:124. doi: 10.4103/abr.abr_15_21. eCollection 2022.
2
Work-up for Incidentally Detected NAFLD: How Far is It Worth?偶然发现的非酒精性脂肪性肝病的检查评估：其价值几何？
Euroasian J Hepatogastroenterol. 2022 Jul;12(Suppl 1):S26-S36. doi: 10.5005/jp-journals-10018-1364.
3
Expression of Jejunal Taste Receptors in Women with Morbid Obesity.肠味觉受体在病态肥胖女性中的表达。
Nutrients. 2021 Jul 16;13(7):2437. doi: 10.3390/nu13072437.
本文引用的文献
1
What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?非酒精性脂肪性肝病目前的药物治疗方法有哪些？
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):232-238. doi: 10.1016/j.jceh.2020.09.001. Epub 2020 Sep 3.
2
Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?肝细胞癌筛查与非酒精性脂肪性肝病：二者有何不同？
J Clin Exp Hepatol. 2020 Sep-Oct;10(5):518-524. doi: 10.1016/j.jceh.2020.04.004. Epub 2020 Apr 18.
3
Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.单纯性脂肪变性或非酒精性脂肪肝的自然史
J Clin Exp Hepatol. 2020 May-Jun;10(3):255-262. doi: 10.1016/j.jceh.2019.09.005. Epub 2019 Sep 20.
4
NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?非酒精性脂肪性肝病中的非侵入性生物标志物：我们做到了吗？
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):88-98. doi: 10.1016/j.jceh.2019.09.006. Epub 2019 Sep 21.
5
Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.非酒精性脂肪性肝病的肝外表现：综述
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):81-87. doi: 10.1016/j.jceh.2019.07.008. Epub 2019 Jul 25.
6
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.过氧化物酶体增殖物激活受体及其激动剂在非酒精性脂肪性肝病中的作用
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):731-739. doi: 10.1016/j.jceh.2019.06.004. Epub 2019 Jul 2.
7
Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的抗糖尿病药物与他汀类药物
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):723-730. doi: 10.1016/j.jceh.2019.06.003. Epub 2019 Jun 27.
8
Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults?儿童和青少年非酒精性脂肪性肝病：它与成人的情况不同吗？
J Clin Exp Hepatol. 2019 Nov-Dec;9(6):716-722. doi: 10.1016/j.jceh.2019.05.005. Epub 2019 May 31.
9
Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.肝移植后非酒精性脂肪性肝病的预防策略
J Clin Exp Hepatol. 2019 Sep-Oct;9(5):619-624. doi: 10.1016/j.jceh.2019.05.004. Epub 2019 May 30.
10
Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease.糖尿病相关非酒精性脂肪性肝病发病机制中涉及的分子和病理事件。
J Clin Exp Hepatol. 2019 Sep-Oct;9(5):607-618. doi: 10.1016/j.jceh.2018.10.004. Epub 2018 Nov 12.
Zotero 插件